Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Activation of a Latent Epitope Causing Differential Binding of Antineutrophil Cytoplasmic Antibodies to Proteinase 3
Moura, Marta Casal , Thompson, Gwen , Nelson, Darlene R. , Fussner, Lynn A. , Hummel, Amber M., Jenne, Dieter E. , Emerling, Daniel , Kallenberg, Cees G. M., Langford, Carol A. , McCune, W. Joseph, Clair, E. William St. , Ytterberg, Steven R. , Stone, John H. , Robinson, William H. , Casal Moura, Marta , Thompson, Gwen E, Merkel, Peter A , Monach, Paul A , Spiera, Robert F , Stone, John H , Robinson, William H , Fervenza, Fernando C. , Merkel, Peter A. , Monach, Paul A. , Seo, Philip , Spiera, Robert , Specks, Ulrich

Mayo Clinic

Arthritis & Rheumatology | December 14, 2022 | Volume: 75 | Issue: 5 | Pages: 748-759

10.1002/art.42418 | PMID 36515151 Get It

Objective Proteinase 3 (PR3) is the major antigen for antineutrophil cytoplasmic antibodies (ANCAs) in the systemic autoimmune vasculitis, granulomatosis with polyangiitis (GPA). PR3‐targeting ANCAs (PR3‐ANCAs) recognize different epitopes on PR3. This study was undertaken to study the effect of mutations on PR3 antigenicity. Methods The recombinant PR3 variants, iPR3 (clinically used to detect PR3‐ANCAs) and iHm5 (containing 3 point mutations in epitopes 1 and 5 generated for epitope mapping studies) immunoassays and serum samples from patients enrolled in ANCA‐associated vasculitis (AAV) trials were used to screen for differential PR3‐ANCA binding. A patient‐derived monoclonal ANCA 518 (moANCA518) that selectively binds to iHm5 within the mutation‐free epitope 3 and is distant from the point mutations of iHm5 was used as a gauge for remote epitope activation. Selective binding was determined using inhibition experiments. Results Rather than reduced binding of PR3‐ANCAs to iHm5, we found substantially increased binding of the majority of PR3‐ANCAs to iHm5 compared to iPR3. This differential binding of PR3‐ANCA to iHm5 is similar to the selective moANCA518 binding to iHm5. Binding of iPR3 to monoclonal antibody MCPR3‐2 also induced recognition by moANCA518. Conclusion The preferential binding of PR3‐ANCAs from patients, such as the selective binding of moANCA518 to iHm5, is conferred by increased antigenicity of epitope 3 on iHm5. This can also be induced on iPR3 when captured by monoclonal antibody MCPR2. This previously unrecognized characteristic of PR3‐ANCA interactions with its target antigen has implications for studying antibody‐mediated autoimmune diseases, understanding variable performance characteristics of immunoassays, and design of potential novel treatment approaches. image
A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes
Wilke, Benjamin K. , Garner, Hillary W. , Bestic, Joseph M. , Chase, Lori A. , Heckman, Michael G. , Schoch, Jennifer J. , Attia, Steven , Heckman, Michael G , Wilke, B K , Garner, Hillary W

Mayo Clinic

Clinical Cancer Research | December 1, 2022 | Volume: 29 | Issue: 3 | Pages: 541-547

10.1158/1078-0432.ccr-22-2732 | PMID 36455003 Get It

Abstract Purpose: The purpose of this pilot study was to examine the clinical efficacy and safety of serial triamcinolone injections for the treatment of desmoid tumors. Patients and Methods: Nine patients were enrolled into this prospective study and underwent three serial ultrasound-guided triamcinolone injections (120 mg) at 6-week intervals. MRI was compared at baseline and every 6 months, out to 24 months. Safety and tolerability were assessed by clinical evaluation and questionnaires, including the 12-item short form survey (SF-12), visual analog scale (VAS), and desmoid patient-reported outcome (PRO) tool. Results: At 24 months, 8 (88.9%) patients demonstrated a reduction in the volume of their tumor while 1 (11.1%) enlarged. Median tumor volume change was −26.9% (−81.1% to 34.6%; P = 0.055) All 9 tumors remained stable based on World Health Organization criteria, whereas 2 (22.2%) demonstrated partial response based on RECIST. There was a significant decrease in the tumor:muscle postcontrast mean signal intensity ratio at 6 months (P = 0.008) and 24 months (P = 0.004). There was a similar decrease in the tumor:muscle T2 mean signal intensity ratio at 24 months (P = 0.02). We found no difference in the SF-12 and VAS scores, but there were significant improvements in the desmoid PRO. Conclusions: Treatment of desmoid tumors with serial triamcinolone injections appears safe and well tolerated by patients, with a 22% partial response based on RECIST. Further research is needed to confirm our results and determine factors predictive of response.
Abstract A003: Risks of ductal carcinoma in situ of the breast associated with pathogenic variants in cancer predisposition genes
Couch, Ronan E. , LaDuca, Holly , Goldgar, David E. , Pesaran, Tina , Dolinsky, Jill S. , Teras, Lauren R., Patel, Alpa V. , Ruddy, Kathryn J. , Vachon, Celine M. , Yao, Song, Huang, Huaizhi , Yadav, Siddhartha , Polley, Eric C. , Boddicker, Nicholas , Na, Jie , Gnanaolivu, Rohan , Hart, Steven N. , Palmer, Julie R. , Teras, Lauren R. , Olson, Janet E. , Vachon, Celine M. , Kraft, Peter , Yao, Song , Trentham‐Dietz, Amy , Nathanson, Katherine L. , Weitzel, Jeffrey N. , Domchek, Susan M. , Couch, Fergus J. , Hu, Chunling

Mayo Clinic

Cancer Prevention Research | December 1, 2022 | Volume: 15 | Issue: 12_Supplement_1 | Pages: A003-A003

10.1158/1940-6215.dcis22-a003 Get It

Abstract Introduction: The relationship between germline pathogenic variants (PVs) in cancer predisposition genes and ductal carcinoma in situ (DCIS) is not well established. The objective of this study is to determine the risks of DCIS and contralateral breast cancer among women with DCIS associated with germline PVs in cancer predisposition genes. Methods: Associations between pathogenic variants in 11 cancer predisposition genes (ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, MSH6, PALB2, RAD51C, and RAD51D) and DCIS were determined in case control analyses of a population-based cohort of 3876 women with DCIS and age-matched unaffected women, and in a clinical cohort of 9887 DCIS cases undergoing clinical genetic testing at Ambry Genetics and unaffected reference controls. The incidence of contralateral breast cancer risk in BRCA1, BRCA2, and PALB2 PV carriers with DCIS was also evaluated in a time-to-event analysis. Results: The mean age at diagnosis of DCIS was 50 years in the clinical testing cohort and 59 years in the population-based cohort. The frequency of PVs in 11 predisposition genes among DCIS cases was 6.9% in the clinical testing cohort and 4.9% in the population-based cohort. PVs in ATM, BRCA1, BRCA2, CHEK2, MSH6, PALB2, and RAD51D were associated with significantly increased risks (Odds Ratio (OR) >2) of DCIS in the clinical testing cohort whereas only PVs in BRCA1, CHEK2, PALB2, and ATM were associated with significantly increased risks of DCIS in the population-based cohort. The cumulative incidence of contralateral breast cancer among BRCA1, BRCA2, and PALB2 PV carriers with DCIS was 11% in 5-years and 20% in 15-years. Conclusions: This study provides new insights into PVs that predispose to DCIS. In addition, it establishes an increased risk of contralateral breast cancer risk among women with DCIS who are carriers of PVs in BRCA1, BRCA2, or PALB2. These findings will guide surveillance and risk reducing strategies in germline PV carriers with DCIS. Citation Format: Huaizhi Huang, Ronan E. Couch, Holly LaDuca, Siddhartha Yadav, Eric C. Polley, Nicholas J. Boddicker, Jie Na, Rohan D. Gnanaolivu, David E. Goldgar, Tina Pesaran, Steven N. Hart, Jill S. Dolinsky, Julie R. Palmer, Lauren Teras, Alpa V. Patel, Kathryn J. Ruddy, Janet E. Olson, Celine M. Vachon, Peter Kraft, Song Yao, Amy Trentham-Dietz, Katherine L. Nathanson, Jeffrey N. Weitzel, Susan M. Domchek, Fergus J. Couch, Chunling Hu. Risks of ductal carcinoma in situ of the breast associated with pathogenic variants in cancer predisposition genes [abstract]. In: Proceedings of the AACR Special Conference on Rethinking DCIS: An Opportunity for Prevention?; 2022 Sep 8-11; Philadelphia, PA. Philadelphia (PA): AACR; Can Prev Res 2022;15(12 Suppl_1): Abstract nr A003.
Abstract 364: Vascular Endothelial Growth Receptor 2 (Flk1) Donor Exosomes Drive Angiogenesis
Rizzo, Skylar A. , Mahlberg, Ryan , Amontree, Ashley, Peterson, Timothy E., Bagwell, Monique, Arrell, D. Kent , Witt, Tyra A. , Nagel, Mary, Park, Sungjo , Sabbah, Michael S. , Li, Mark , Kargaran, Parisa K, Wu, Yue , Li, Jialun , Moran, Steven L. , Shi, Ao , Bagwell, Monique S , Nagel, Mary, Kim, Yohan , Lucien, Fabrice , Terzic, André , Behfar, Atta

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | November 30, 2022 | Volume: 42 | Issue: Suppl_1 | Pages: No page available

10.1161/atvb.42.suppl_1.364 Get It

Objectives: Peripheral arterial disease is a significant cause of morbidity and mortality. The goal of this study was to develop a novel treatment to promote angiogenesis. Platelets have been previously implicated in angiogenic events; however, platelet activation rather than presence of growth factors has been associated with new blood vessel formation. This study evaluated exosomes purified from activated platelets to determine their potential in promoting angiogenesis both in vitro and in vivo. Methods & Results: Under Current Good Manufacturing Practices, conditioned medium processed from apheresis platelet cultures yielded a purified exosome product (PEP) enriched for CD63, CD9 and Alix. In vitro, PEP drove HUVEC proliferation, migration, and vascular tube formation. Proteomic evaluation showed Flk1 (VEGFR2) was one of the key angiogenic proteins in PEP. HUVECs treated with Flk1 antibody neutralized PEP (anti-Flk1-PEP) showed reduced vascular tube formation compared to PEP. To evaluate in vivo angiogenesis, a rodent model of hindlimb ischemia was treated with sustained release PEP embedded in fibrin glue (PEP/TISSEEL) with blood flow evaluated by SPY angiography at 28 days post-treatment. Animals treated with PEP/TISSEEL showed improved blood flow with significant difference (p<0.001) as compared to sham, TISSEEL, and anti-Flk1-PEP/TISSEEL. Muscle tissue stained with α smooth muscle actin showed a significant increase (p<0.001) in vascular area in PEP/TISSEEL treated animals compared to TISSEEL alone. To further evaluate clinical translatability, a rabbit ear ischemia wound model was then treated with PEP/TISSEEL. Rabbit ears showed accelerated wound healing and restored blood flow on SPY angiography. Histologic evaluation of vascular area showed a significant increase in vascular area (p<0.05) compared to sham and TISSEEL alone animals. Conclusions: Exosome driven donation of Flk1 here promoted angiogenic events and was successfully translated into healing outcomes in the setting of two animal models of peripheral ischemia. This novel insight into biotherapy achievable pro-angiogenesis establishes a clinical-grade off-the-shelf exosome technology for the treatment of peripheral vascular disease.
Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis
Wang, Jacqueline F, Jiang, Yi , Qi, Xinyue , Hampel, Paul J. , Leis, José F., Thanarajasingam, Gita , Inwards, David J. , Nowakowski, Grzegorz S. , Ansell, Stephen M. , Wang, Jacqueline , Wang, Jacqueline F , Hwang, Steven R. , Zhang, Shijia , Parikh, Sameer A. , Ding, Wei , Kenderian, Saad S. , Muchtar, Eli , Muñoz, Javier , Paludo, Jonas , Habermann, Thomas M. , Witzig, Thomas E. , Kay, Neil E. , Zhou, Shouhao , Wang, Yucai

Mayo Clinic

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9882-9884

10.1182/blood-2022-168152 Get It

Mogamulizumab-Associated Rash (MAR) Correlates with Longer Progression Free Survival in Cutaneous T Cell Lymphoma (CTCL)
Hu, Bei , Sokol, Lubomir, Ayers, Amy , Castillo, Luis Enrique Malpica , Hwang, Steven R, Wada, David A., Moyo, Tamara K. , Atrash, Shebli , Cohen, Leah, Barta, Stefan K , Zhang, Yumeng , Bennani, N. Nora , Tun, Aung M. , Ghosh, Nilanjan , Shinohara, Michi M.

Mayo Clinic

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1488-1490

10.1182/blood-2022-166887 Get It

Treatment Patterns and Outcomes of Patients with Chronic Lymphocytic Leukemia with TP53 Mutations
He, Rong , Hampel, Paul J. , Call, Timothy G. , Koehler, Amber B. , Behnken, Amy, Leis, José F., Viswanatha, David S., Dyke, Daniel L. Van , Hwang, Steven R. , Wang, Yucai , Rabe, Kari G. , Kenderian, Saad S. , Muchtar, Eli , Kay, Neil E. , Braggio, Esteban , Shi, Min , Slager, Susan L. , Parikh, Sameer A. , Ding, Wei

Mayo Clinic

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12390-12392

10.1182/blood-2022-165508 Get It

Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting
Bock, Allison M. , Tawfiq, Reema, Poonsombudlert, Kittika , Maliske, Seth , Kabat, Brian, Gysbers, Brianna, Smith, Katherine E. , Inwards, David J. , Ansell, Stephen M. , Nowakowski, Grzegorz S. , Smith, Katherine E R , Gile, Jennifer , Larson, Melissa C. , Maurer, Matthew J. , Cerhan, James R. , Hwang, Steven R. , Paludo, Jonas , Habermann, Thomas M. , Ayyappan, Sabarish Ram , Witzig, Thomas E. , Farooq, Umar , Wang, Yucai

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6517-6519

10.1182/blood-2022-165419 Get It

Ultrasound-Guided Percutaneous Peripheral Nerve Stimulation for Chronic Refractory Neuropathic Pain: a Unique Series
Ferreira‐Silva, Nuno , Ferreira‐Dos‐Santos, Guilherme , Gupta, Sahil , Eldrige, Jason S. , Pingree, Matthew J. , Clendenen, Steven R. , Hurdle, Mark Friedrich B., Hunt, Christine L., Ferreira-Silva, Nuno , Hunt, Christine

Mayo Clinic

Pain Management | November 21, 2022 | Volume: 13 | Issue: 1 | Pages: 15-24

10.2217/pmt-2022-0070 | PMID 36408639 Get It